ACE2 and COVID-19: Since ACE2 expressed on the adipocytes of obese patients and is a target molecule for SARS-CoV-2, this interaction leads to hyperactivation of the RAS pathway, which has been investigated as one of the potential mechanisms contributing to the worse prognosis of COVID-19 subjects with concomitant obesity.